Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780650 · ClinicalTrials.gov registry record · Early Phase 1
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 56
- Enrollment target
NCT00780650 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 56 participants.
The verdict
NCT00780650, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is aimed at determining if the drug Atomoxetine (Strattera-used to treat Attention Deficit Hyperactivity Disorder(ADHD) has effects on the body's ability to defend itself against low blood sugar.
Interventions
- DRUG Placebo
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-05 |
| Est. Completion | 2018-08-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780650
The ClinicalTrials.gov registry entry for NCT00780650 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00780650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00780650 about?
NCT00780650 is a clinical study titled "Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine". This study is aimed at determining if the drug Atomoxetine (Strattera-used to treat Attention Deficit Hyperactivity Disorder(ADHD) has effects on the body's ability to defend itself against low blood sugar.
What is the current status of trial NCT00780650?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 56 participants. The study started on 2009-05. Estimated completion is 2018-08-21.
What interventions are being tested in trial NCT00780650?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00780650?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.